Checkpoint Inhibitor Pneumonitis — Real-World Incidence and Risk

Journal of Thoracic Oncology - United States
doi 10.1016/j.jtho.2018.10.007
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Elsevier BV

Related search

Clinical Features, Diagnostic Challenges, and Management Strategies in Checkpoint Inhibitor-Related Pneumonitis

Cancer Management and Research
Oncology
2017English

The Alveolar Immune Cell Landscape Is Dysregulated in Checkpoint Inhibitor Pneumonitis

Journal of Clinical Investigation
Medicine
2019English

High Mortality and Poor Treatment Efficacy of Immune Checkpoint Inhibitors in Patients With Severe Grade Checkpoint Inhibitor Pneumonitis in Non‐small Cell Lung Cancer

Thoracic Cancer
MedicinePulmonaryRespiratory MedicineOncology
2019English

Trends in Checkpoint Inhibitor Therapy for Advanced Urothelial Cell Carcinoma at the End of Life: Insights From Real‐World Practice

Oncologist
Cancer ResearchMedicineOncology
2019English

Kombinationstherapie Mit Checkpoint-Inhibitor

Uro-News
2017English

Incidence of Immune Checkpoint Inhibitor-Associated Diabetes: A Meta-Analysis of Randomized Controlled Studies

Frontiers in Pharmacology
Pharmacology
2019English

Risk of Pneumonitis and Pneumonia Associated With Immune Checkpoint Inhibitors for Solid Tumors: A Systematic Review and Meta-Analysis

Frontiers in Immunology
AllergyImmunology
2019English

Estimating Systematic Risk in Real-World Networks

Lecture Notes in Computer Science
Computer ScienceTheoretical Computer Science
2014English

Pnd19 - Incidence of Epilepsy After Strokes and Real-World Antiepileptic Drug Treatment

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy